While Syndax Pharmaceuticals Inc has overperformed by 0.43%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SNDX fell by -30.03%, with highs and lows ranging from $25.07 to $8.58, whereas the simple moving average fell by -33.49% in the last 200 days.
On July 10, 2025, Goldman started tracking Syndax Pharmaceuticals Inc (NASDAQ: SNDX) recommending Buy. A report published by UBS on October 24, 2024, Initiated its previous ‘Buy’ rating for SNDX. Jefferies also rated SNDX shares as ‘Buy’, setting a target price of $37 on the company’s shares in an initiating report dated June 28, 2024. Scotiabank January 31, 2024d the rating to Sector Perform on January 31, 2024, and set its price target from $36 to $23. Mizuho initiated its ‘Buy’ rating for SNDX, as published in its report on December 22, 2023. BofA Securities’s report from October 25, 2023 suggests a price prediction of $29 for SNDX shares, giving the stock a ‘Buy’ rating. Goldman also rated the stock as ‘Buy’.
Analysis of Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -93.70% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.75, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and SNDX has an average volume of 2.23M. On a monthly basis, the volatility of the stock is set at 5.89%, whereas on a weekly basis, it is put at 6.08%, with a gain of 0.11% over the past seven days. Furthermore, long-term investors anticipate a median target price of $32.67, showing growth from the present price of $9.25, which can serve as yet another indication of whether SNDX is worth investing in or should be passed over.
How Do You Analyze Syndax Pharmaceuticals Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.16%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 115.59% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
SNDX shares are owned by institutional investors to the tune of 115.59% at present.
